Keros Therapeutics Appoints Experienced Healthcare Finance Executive Charles Newton to Board
KROS sits 65% above its 52-week low of $9.12.
Summary
Keros Therapeutics announced the appointment of Charles Newton, a seasoned healthcare finance executive and former CFO of Lyell Immunopharma, to its Board of Directors, while Dr. Carl Gordon will resign.
Key Events · Executive and Board Changes · KROS
-
New Director Appointed
Charles Newton, former CFO of Lyell Immunopharma and a veteran in healthcare investment banking, joins the Board of Directors effective March 9, 2026.
-
Board Committee Appointments
Mr. Newton will serve on both the Compensation Committee and the Audit Committee.
-
Director Resignation
Dr. Carl Gordon will resign from the Board and Compensation Committee, effective March 9, 2026, with no stated disagreements.
-
Director Compensation
Mr. Newton will receive standard non-employee director compensation, including initial equity grants valued at $300,000 and annual cash and equity retainers.
Analysis · KROS · Life Sciences
The appointment of Charles Newton significantly strengthens Keros Therapeutics' board with his extensive background in healthcare investment banking and as a former CFO of a biopharma company. His expertise in capital markets and navigating clinical program value inflection points will be invaluable as Keros advances its pipeline. The simultaneous resignation of Dr. Carl Gordon is noted as not being due to any disagreement, indicating a smooth transition rather than a concerning departure. This move enhances corporate governance and strategic financial oversight for the clinical-stage biopharmaceutical company.
At the time of this filing, KROS was trading at $15.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $457.9M. The 52-week trading range was $9.12 to $22.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.